Connect with us

Press Release

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Published

2 years ago

on

–News Direct–

By Jeremy Golden, Benzinga

Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023.

The randomized, controlled clinical trial is specifically looking into the safety and efficacy of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection if possible in borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Very encouraging results were recently reported by the Needham, Massachusetts-based company.

Patients reached an estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group in PDAC. At 24 months, the survival rate was 71.4% in CAN-2409 treated patients compared to only 16.7% in the control group after chemoradiation. Thus, prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC. Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients in the randomized control SoC chemotherapy group remained alive at the data cut-off (50.6 months).

No new safety signals were observed, providing further support that multiple injections of CAN-2409 are generally well tolerated. Additionally, there were no dose-limiting toxicities or cases of pancreatitis reported.

Previous analysis of resected tumors showed dense aggregates of immune cells including CD8+, cytotoxic tumor-infiltrating lymphocytes and dendritic cells in PDAC tissue after CAN-2409 administration. This reinforces the potential of CAN-2409 to activate a robust antitumoral immune response in patients with cancer also in cold, immunosuppressive tumors like PDAC.

Given the frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed, said Garrett Nichols, MD, MS, Chief Medical Officer of Candel. We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data in this randomized clinical trial. CAN-2409 was generally well tolerated without significant additional local or systemic toxicity when added to SoC chemoradiation.

Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf, replication-defective adenovirus designed to induce an individualized, systemic immune response against the tumor. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. More than 1,000 patients have been dosed with CAN-2409 to date, with a favorable reported tolerability profile and proof of concept in each indication that the company is currently pursuing.

CAN-2409 is injected directly into the tumor or target tissue using a localized injection method that is akin to the standard approach for in situ vaccination to elicit an immune response against the injected tumor and uninjected metastases.

Long-term survival data in PDAC was recently updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to Candel Therapeutics for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023. More recently, the FDA also granted Orphan Drug Designation.

The failure of conventional immunotherapy to improve outcomes in pancreatic cancer is attributed to the highly immunosuppressive tumor microenvironment, which is largely devoid of immune cells, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. The immunological changes induced by CAN-2409, evident in the pancreatic tissue and the peripheral blood after administration, suggest that CAN-2409 is able to change the balance between the tumor and the patients anti-tumor immune response, which can convert progressive cancer into a chronic disease associated with improved survival.

Featured photo by National Cancer Institute on Unsplash.

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Aljanae Reynolds

+1 617-916-5445

areynolds@wheelhouselsa.com

Company Website

https://www.candeltx.com/

View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-reports-positive-data-from-phase-2-trial-of-can-2409-in-borderline-resectable-pancreatic-cancer-425692953

Candel Therapeutics

comtex tracking

COMTEX_453283087/2655/2024-06-03T08:31:08

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Malaysia’s AI Future Takes Centre Stage as World AI Show Returns for Its 48th Global Edition

Published

2 hours ago

on

August 13, 2026

By

Kuala Lumpur, 13 August 2026, ZEX PR WIRE — Artificial intelligence has moved beyond being an emerging technology to become a defining pillar of Malaysia’s economic and digital ambitions. As the country accelerates investments in AI infrastructure, sovereign cloud capabilities, and enterprise-wide transformation, the focus has shifted from experimentation to execution. Against this backdrop, World AI Show Malaysia returns for its 48th Global Edition on 9–10 September 2026 at DoubleTree by Hilton Kuala Lumpur, Malaysia, convening the policymakers, enterprise leaders, technology pioneers, investors, and innovators who are shaping the country’s next chapter of AI-led growth. 

Presented by Trescon, World AI Show Malaysia carries this year’s tagline, “Where Malaysia’s AI Decisions Get Made.” As the country transitions into a strategic AI hub for Southeast Asia and organisations across both the public and private sectors define their AI roadmaps, modernise digital infrastructure, and establish governance frameworks for responsible innovation, the event will provide an executive platform dedicated to meaningful dialogue, strategic partnerships, and commercially relevant outcomes. 

The programme has been curated to address the opportunities and complexities surrounding enterprise AI adoption, sovereign cloud, intelligent infrastructure, cybersecurity, data governance, and responsible AI implementation. Over two days, attendees will engage through keynote addresses, executive panel discussions, fireside conversations, invitation-only boardroom sessions, technology showcases, curated networking engagements, and business meetings designed to facilitate knowledge exchange and cross-sector collaboration. 

The conference will feature an impressive line-up of distinguished government and industry leaders, including: 

  • Budiman Bujang, Deputy Chief Digital Officer, Johor Corporation 

  • Ts. D. Jackson Raao, Principal Assistant Secretary, Ministry of Science, Technology and Innovation (MOSTI) 

  • Jamie Tan, Managing Director, JLL Malaysia 

  • Ganeshbabu Nagarajan, Executive Director – Transformation Programmes, Standard Chartered Bank 

  • Chua Yong Howe, Chief Digital Officer, UEM Edgenta Berhad 

  • Shahrin Oli Mohamed, Group Chief Technology Officer, Pos Malaysia Berhad 

  • Keeratpal Singh, Chief AI and Data Officer (APAC Financial Services), Worldline 

  • Dr. Sadesh Manikam, Executive Vice President, Enterprise Data Office & Data Protection Officer, Bursa Malaysia 

  • Ts. Zairil Anuar Ahmad, Chief Technology Officer, Co-opbank Pertama 

  • Ahmad Faiz, Head – Data & AI, Global Technology Unit, BASF 

  • Raunak Mehta, Chief Executive Officer, Igloo 

  • Muhammad Najib Masdan, Senior Vice President, Khazanah Nasional Berhad 

  • Ts. Narayanan Chidambaram, Head Project Engineering Pod (Technology & Digital PE&T – Digital Project Management) PETRONAS 

  • Mohamed Aafrin, Director of Engineering, DKSH 

  • Sudeep Srivastava, Head – KL IT Center SLB (Schlumberger)  

  • Hong H. Ong, Director of Digital Technology, Labuan Financial Services Authority 

  • Mohd Hanapi Bisri, Senior Digital Industry Leader- Oil & Gas 

  • Dario Bianchi, Chief Product Officer, Mindvalley 

  • G Saravanan, Chief Information Officer, National Cancer Society Malaysia 

 

Reflecting on Malaysia’s AI trajectory, Ts. D. Jackson Raao, Principal Assistant Secretary, MOSTI, said: 

“Malaysia is at a pivotal stage where artificial intelligence is becoming a key driver of national transformation. As we accelerate AI adoption across industries, our focus must remain on responsible innovation, robust governance, strong cybersecurity, and developing a future-ready talent ecosystem. By doing so, Malaysia is well-positioned to emerge as a trusted regional leader in safe and sustainable AI innovation.”

An ecosystem of public sector and technology organisations is supporting this year’s edition. CyberSecurity Malaysia joins as the Supporting Partner, reinforcing the importance of building a secure and trusted digital ecosystem. 

Datadog joins as the Lead Sponsor, Magure as the Platinum Sponsor, Bitdeer AI as the Gold Sponsor, and Alibaba Cloud and Unison Consulting Sdn Bhd as Bronze Sponsors. The exclusive CXO Boardroom sessions will be powered by Zoom and Datadog, while CloudSpace will participate as an exhibitor, showcasing cloud and AI capabilities to enterprise decision-makers. 

Designed exclusively for senior executives, government representatives, and technology leaders, World AI Show Malaysia 2026 will provide a platform where strategic priorities are translated into actionable partnerships, investment opportunities, and real-world AI deployments. As Malaysia continues to strengthen its position within the regional AI landscape, the summit is set to become a key meeting point for organisations shaping the future of intelligent enterprise across Southeast Asia. 

CLAIM YOUR DELEGATE PASS:  Click here

For sponsorship opportunities, speaking engagements, or attendance information, please contact: 

Shrikanth Prabhu
Commercial Director 
Email: prabhu@tresconglobal.com 
Mobile: +91 8660115892

Media Contact: 
Reeha Haris 
Media & PR Executive
Email: reeha@tresconglobal.com 
Mobile: +91 8848655312 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Phomemo Expands Tattoo Stencil Printer Solutions to Support Professional Artists Evolving Workflows

Published

2 hours ago

on

August 13, 2026

By

New York, New York, United States, 13th Aug 2026 – Phomemo, a global creative printing brand specializing in thermal printing solutions, has expanded its tattoo stencil printer lineup with two new solutions — the Phomemo TA81 Large-Format Tattoo Stencil Printer and Phomemo L85 Smart Touchscreen Tattoo Stencil Printer — designed to support the evolving needs of professional tattoo artists.

From large-scale body art preparation to everyday studio workflows, different tattoo projects require different printing solutions. While some artists prioritize portability and flexibility, others need tools that can handle full-length designs, customized layouts, and more efficient preparation processes.

Alongside established models including the M08F-WS and M08F Plus, Phomemo’s expanded tattoo printer lineup provides artists with multiple options based on their creative style, workflow, and studio needs.

Choosing the Right Tattoo Stencil Printer Matters

For tattoo artists, stencil preparation is an important step between digital design and the final artwork on skin. A reliable tattoo stencil printer can help artists maintain design accuracy, reduce preparation time, and create a smoother workflow before each session.

However, different tattoo styles create different challenges.

Artists specializing in fine details may prioritize clear and portable printing solutions, while those creating sleeves, back pieces, or large-scale compositions often face a different challenge: preparing oversized stencils without manually assembling multiple sections.

Phomemo’s tattoo stencil printer solutions are designed around these different creative scenarios.

Phomemo TA81: A Large-Format Tattoo Stencil Printer Built for Complex Designs

For artists who regularly create full sleeves, back pieces, legs, or other large-scale tattoo projects, stencil preparation can become one of the most time-consuming parts of the workflow.

Traditionally, oversized tattoo designs often require artists to print multiple stencil sheets, trim edges, align different sections, and carefully transfer the assembled design onto the skin. While this approach can work, maintaining accuracy across a large composition can add extra preparation steps and increase the risk of misalignment.

The Phomemo TA81 was designed to address this challenge with continuous, variable-length stencil printing.

Unlike standard sheet-based printing methods, the TA81 uses a roll-fed system that allows artists to print large tattoo designs in one continuous piece. For full sleeves, back pieces, spine designs, or other extended compositions, artists can create a complete stencil without manually cutting and joining multiple sections.

This one-piece printing workflow helps maintain design continuity and makes stencil preparation more efficient for complex tattoo projects.

Beyond size capability, the TA81 focuses on reducing waste during professional workflows. Its variable-length printing system allows artists to print only the required length for each design rather than relying on fixed-size sheets. For busy studios handling multiple projects, this can help optimize transfer paper usage during daily operations.

The TA81 also features Phomemo’s wrinkle-resistant printing technology, designed to help keep transfer paper flat during longer printing processes. Combined with an upgraded print head and edge-stabilizing design, the printer helps deliver consistent and clear stencil lines throughout the entire design.

With Bluetooth and USB connectivity support, the TA81 can connect with smartphones, tablets, laptops, and desktops across Android, iOS, Windows, macOS, and ChromeOS systems, giving artists flexibility when preparing designs.

Through the Phomemo App, artists can adjust designs, preview tattoo layouts, split large images, manage transfer settings, and prepare files before printing.

Phomemo L85: Smart Touchscreen Control for a More Customized Workflow

While large-scale artists may prioritize printing size and efficiency, other tattoo professionals look for a more interactive and customizable stencil preparation experience.

The Phomemo L85 is designed for artists who prefer a smarter workflow with direct control through an integrated touchscreen.

Featuring a 5-inch touchscreen with six language options, the L85 allows artists to manage printing tasks directly from the device. Functions such as template selection, brightness adjustment, print mileage tracking, battery information display, timer settings, sensor calibration, and self-testing can be accessed without relying entirely on another device.

For artists working with different tattoo styles and design formats, flexibility is also important. The L85 supports multiple print sizes, including Letter, A4, B5, A5, and additional width options, allowing artists to prepare different stencil layouts based on their projects.

The L85 also works with the Phomemo App ecosystem, providing creative and editing tools such as image transformation, tattoo extraction, line-art conversion, tattoo preview, and large-image splitting.

Optional AI-assisted features, including AI image generation and tattoo extraction, are designed to support artists during the preparation stage by helping explore ideas, refine concepts, and improve workflow efficiency — while keeping the artist’s own creativity and craftsmanship at the center of the design process.

Portable Tattoo Stencil Solutions: M08F-WS and M08F Plus

For artists who prioritize mobility, Phomemo also offers portable tattoo stencil printer solutions designed for flexible everyday workflows.

The Phomemo M08F-WS provides a lightweight wireless printing solution for artists who need a compact setup. Supporting Bluetooth connectivity and multiple operating systems, it allows artists to prepare tattoo stencils from smartphones, tablets, laptops, and desktops.

The Phomemo M08F Plus builds on this portable concept with a smarter touchscreen experience. Its built-in touchscreen supports functions including brightness adjustment, auto shutdown, calibration, and self-test printing, helping artists complete basic operations directly from the printer.

With thermal printing technology, both models eliminate the need for ink cartridges while providing a convenient solution for tattoo stencil preparation. Through the Phomemo App, artists can access editing tools, stencil generation, previews, and other workflow features designed to simplify the transition from digital artwork to physical stencil.

Choosing the Right Phomemo Tattoo Stencil Printer

Every tattoo artist has a different creative workflow, and the ideal tattoo stencil printer depends on the type of work being created. All can be found on Phomemo’s official site.

Artists working on large-scale compositions such as sleeves and back pieces may benefit from the Phomemo TA81’s continuous full-length printing capability.

Artists looking for a smart, customizable printing experience can explore the Phomemo L85 with touchscreen control and flexible print options.

Artists who need a portable solution for everyday stencil preparation can choose between the lightweight M08F-WS and the upgraded M08F Plus.

By developing tattoo stencil printers for different artistic scenarios, Phomemo continues to help tattoo professionals simplify preparation, improve efficiency, and focus more on the creative process.

About Phomemo

Phomemo is a global creative printing brand dedicated to making everyday printing simple, enjoyable, and accessible. Backed by over 12 years of expertise in thermal printing technology and trusted by over 40 million users worldwide, Phomemo continues to develop the evolution of smart printing. From home organization to global e-commerce, Phomemo lowers the barrier to professional results, enabling ideas and commerce to flow freely.

Media Contact

Organization: Phomemo

Contact Person: Alicia Chen

Website: https://phomemo.com

Email:
influencerscenter@phomemo.com

City: New York

State: New York

Country:United States

Release id:48084

The post Phomemo Expands Tattoo Stencil Printer Solutions to Support Professional Artists Evolving Workflows appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026

Published

2 hours ago

on

August 13, 2026

By

Hong Kong, Hong Kong, August 13th, 2026, FinanceWire

SBCFX has announced its participation in iFX EXPO Asia 2026, one of the leading B2B exhibitions for the online trading, fintech, and financial services sectors. 

Scheduled to take place on 8–9 October 2026 at the Hong Kong Convention and Exhibition Centre (HKCEC), the event is expected to attract a diverse range of industry stakeholders, including brokers, traders, investors, Introducing Brokers (IBs), affiliates, fintech companies, liquidity providers, and financial services professionals from across Asia and beyond. 

As part of its ongoing international expansion strategy, SBCFX will showcase its integrated trading ecosystem, including the MetaTrader 5 (MT5) platform, multi-asset CFD trading capabilities, institutional-grade liquidity services, and its latest digital trading solutions. The company will also use the exhibition as a platform to share its growth strategy, technology roadmap, and long-term vision for the evolving global trading landscape. 

“iFX EXPO Asia represents an important opportunity for SBCFX to strengthen its engagement with the Asian trading community and further expand its regional network,” said David, CEO of SBCFX. 

“Our ambition is to become one of the most trusted global trading brands by bridging technology, education, and market access. We believe the future of online trading is not only about faster execution and better tools, but also about creating an ecosystem where traders, partners, and institutions can grow together. iFX EXPO Asia provides the perfect platform for us to share this vision and connect with the industry.” 

Driving Innovation While Building a Sustainable Trading Ecosystem 

Technology and innovation remain central to SBCFX’s long-term development strategy. The company continues to invest in digital infrastructure, trading technology, and client-focused solutions designed to enhance trading efficiency and improve user experience across global markets. 

Alongside its trading services, SBCFX will soon introduce a new mobile trading application that will provide clients with convenient access to account management, market information, trading tools, and platform services through a unified interface. The upcoming launch reflects the company’s ongoing efforts to improve accessibility and streamline the trading experience for users worldwide.   

Looking ahead, SBCFX remains focused on developing innovative solutions that support traders at every stage of their journey while strengthening connections between retail investors, institutional partners, and the broader financial ecosystem. By combining advanced technology with a client-centric approach, the company aims to create a smarter, more connected trading environment that adapts to the evolving needs of modern market participants. 

During the two-day event, SBCFX representatives will engage with prospective clients, Introducing Brokers, institutional partners, and technology providers to explore strategic collaborations and support the company’s continued growth across Asia. 

Meet SBCFX at Booth 37 

SBCFX welcomes individual traders, Introducing Brokers, affiliates, fintech firms, liquidity providers, institutional investors, and technology partners to visit Booth 37 and learn more about the company’s products, services, and strategic development plans. 

Visitors to the booth will have the opportunity to meet members of the SBCFX team, explore the company’s latest initiatives, and receive a selection of exclusive SBCFX promotional gifts and event merchandise available throughout the exhibition while supplies last. 

To facilitate more in-depth discussions and personalised consultations, attendees are encouraged to schedule a one-on-one meeting with the SBCFX team in advance via the following booking link: 

https://forms.cloud.microsoft/r/QwRd66ZmQa 

Event Details 

Event: iFX EXPO Asia 2026 

Date: 8–9 October 2026 

Time: 10:00 AM – 6:00 PM 

Venue: Hong Kong Convention and Exhibition Centre (HKCEC), Hong Kong 

Booth: 37 

For media enquiries or further information, please contact SBCFX at cs@sbcfx.com. 

About SBCFX 

SBCFX is a global financial services provider committed to delivering innovative online trading solutions supported by advanced technology, institutional-grade liquidity, and exceptional client service. Through continuous investment in technology, regulatory compliance, and strategic partnerships, SBCFX provides access to a wide range of global financial markets while empowering traders, Introducing Brokers, affiliates, and institutional partners to achieve long-term success. 

With a vision to become a trusted global brokerage, SBCFX remains dedicated to transparency, innovation, and sustainable growth, delivering world-class trading solutions to clients around the world. 

Contact

Marketing Executive
Kit Cheung
SBCFX
marketing@sbcfx.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us